Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Sanofi Pasteur SA
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Booster Effect and Safety of a DTaP-IPV-Hib Combined Vaccine, with or without Hep B, in Healthy Subjects 11 to 18 Months of Age Who Received a Hexavalent or Hexavalent/Pentavalent Combined Vaccine during the Primary Series Účinek a bezpečnost přeočkování kombinovanou vakcínou DTaP-IPV-Hib s podáním vakcíny proti hepatitidě B či bez ní u zdravých subjektů ve věku 11 až 18 měsíců, kteří během primární série obdržely hexavalentní nebo hexavalentní/pentavalentní kombinovanou vakcínu
Immunogenicity Groups 1 and 2 • Assess the antibody persistence of DTaP-IPV-HB-Hib or Infanrix hexa following a 3-dose primary series at 2, 3, and 4 months of age (MoA) before the administration of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly subjects
• To describe the immune response of each candidate vaccine 21 days after each vaccination by hemagglutination inhibition (HAI) and seroneutralization (SN) method in all adult and elderly subjects. • ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects
• To describe the immune response of the inactivated, split-virion swine-origin A/H1N1influenza vaccine without adjuvant in each group
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly
• To describe the injection site reactions and systemic safety profile during the 21 days following each of two primary series and one booster (as applicable) intramuscular (IM) injections in two age ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children
• To describe the safety profiles (injection site reactions and systemic events) during the 21 days following each vaccination in subjects receiving the D0-D21 and the D0-D42 vaccination schedules, an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in Mexico
Safety and reactogenicity Viremia Dengue immune responses
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicina...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years
• To describe the immune response of each candidate vaccine 21 days after each vaccination by HAI and SN testing in all subjects. • To describe the safety profiles (injection site reactions, and syste...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Safety and Immunogenicity of Sanofi Pasteur’s DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Primary Series of Vaccination in Infants
To describe the safety and reactogenicity after each and all doses of the study vaccine administered as a 3-dose primary series.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with Intramuscular Vaccination with Vaxigrip® in Adults
To demonstrate that the vaccine administered by the intradermal (ID) route with the new Becton Dickinson (BD) ID system (pre-filled ID system allowing a better ergonomic use) is at least as immunogeni...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant